<DOC>
	<DOCNO>NCT01701349</DOCNO>
	<brief_summary>This multicenter , double-blind , placebo-controlled , randomize study fosbretabulin give chemotherapy ( paclitaxel carboplatin ) compare placebo give chemotherapy ( paclitaxel carboplatin ) subject anaplastic thyroid cancer ( ATC ) . The primary objective study determine overall survival . A maximum 300 subject recruit approximately 75 multinational site approximately 35 locate United States .</brief_summary>
	<brief_title>Fosbretabulin Placebo Combination With Carboplatin/Paclitaxel Anaplastic Thyroid Cancer</brief_title>
	<detailed_description>The Treatment Plan follow subject consist : - A Screening Visit within 14 day study drug ( fosbretabulin placebo ) administration - A Treatment Phase 21-day combination treatment ( study drug plus chemotherapy ) cycle ( 6 cycle ) - An End Treatment Phase assessment - An End Study Visit occur 30 day last day study drug administration , able After last clinic visit , subject follow survival monthly phone call , email , in-person .</detailed_description>
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Thyroid Carcinoma , Anaplastic</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Combretastatin</mesh_term>
	<mesh_term>Fosbretabulin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Unresectable , residual , recurrent persistent ATC , histologically cytologically confirm Prior cytotoxic therapeutic regimen primary therapy curative intent prior target therapy ( TKIs ) eligible ( Prior taxane platinum therapy allow ) Untreated ATC follow biopsy , surgery curative intent , palliation , radiation therapy consider administer without radiosensitizing chemotherapy Disease present clinical exam ( measurable nonmeasurable ) Distant metastases ( Stage IVC ) must histologic confirmation ATC either original primary lesion metastatic site Neoadjuvant therapy radiation either radiosensitizing chemotherapy follow surgery curative intent , palliation , biopsy eligible residual persistent ATC present Subjects tracheostomy eligible ECOG PS 2 less Adequate bone marrow , renal , hepatic function , electrolytes WNL institution Disease able completely resect negative microscopic margin without residual disease body Active brain metastasis , include symptomatic involvement , evidence cerebral edema prior CT MRI , radiographic evidence brain metastasis since definitive therapy , continue requirement corticosteroid cerebral edema History malignancy ACT except prior low grade thyroid malignancy , curatively treat basal cell carcinoma insitu melanoma skin , cervical intraepithelial neoplasia , localized prostate cancer , insitu carcinoma breast Known intolerance hypersensitivity fosbretabulin , paclitaxel , carboplatin component Receiving concurrent investigational therapy receive investigational therapy indication within 28 day first schedule day dose Grade 3 great peripheral neuropathy History prior cerebrovascular event , include transient ischemic attack within past 6 month Uncontrolled hypertension define blood pressure &gt; 150/100 mm Hg despite medication Symptomatic vascular disease ( e.g . intermittent claudication ) History unstable angina pectoris pattern , myocardial infarction ( include nonQ wave ) within past 6 month , NYHA Class III IV congestive heart failure History torsade de pointes , ventricular tachycardia , ventricular fibrillation congenital long QT syndrome . Pathologic bradycardia ( &lt; 60 b/m heart block ( exclude 1st degree block , consist PR interval prolongation ) ECG finding clinically significant ventricular arrhythmia , new ST segment elevation depression , new Q wave ECG ( PVCs exclude ) . QTc interval 480 ms Requirement concurrent treatment drug know prolong QTc interval , include antiarrhythmic medication Potassium and/or magnesium concentration normal range reference laboratory History solid organ bone marrow transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>ATC</keyword>
	<keyword>Anaplastic Thyroid Cancer</keyword>
	<keyword>Stage IVC Anaplastic Thyroid Cancer</keyword>
	<keyword>Thyroid Cancer</keyword>
	<keyword>Head Neck Tumors</keyword>
</DOC>